Agendia, which provides genetic tests designed to guide optimal treatments for breast cancer, filed on Thursday with the SEC to raise up to $75 million in an initial public offering.
The commercial-stage company offers two proprietary tests, MammaPrint and BluePrint, which isolate RNA from tumor tissue to measure gene expression in the most relevant genes for various insights for physicians. Its tests aim to predict the likelihood of recurrence, inform physicians regarding the decision to pursue adjuvant chemotherapy and endocrine therapy, and provide information on breast cancer molecular subtypes (Luminal, HER2, Basal).
Incorporated in the Netherlands but based in Irvine, CA, the company was founded in 2003 and booked $61 million in revenue for the 12 months ended September 30, 2021. It plans to list on the Nasdaq under the symbol AGDX. Agendia filed confidentially on August 23, 2021. Goldman Sachs, Citi, Cowen, and Stifel are the joint bookrunners on the deal. No pricing terms were disclosed.
